RFCA
AUPH icon

R&F Capital Advisors’s Aurinia Pharmaceuticals AUPH Stock Holding History

R&F Capital Advisors’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		$313K Buy
+42,576
New +$197K 0.08% 390

Other funds holding AUPH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CLCM
Crawford Lake Capital Management Lakewood, New Jersey $87.4M AUM 30.13% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

R&F Capital Advisors's AUPH Position: Q1 2017 in Review

R&F Capital Advisors opened a new position in Aurinia Pharmaceuticals (AUPH) in Q1 2017: 42,576 shares worth $313K. The stake represents 0.08% of the portfolio and ranks #390 among its holdings.

71 funds tracked by Wall St. Rank hold AUPH as of Q1 2017.

  • R&F Capital Advisors held 42,576 shares of Aurinia Pharmaceuticals worth $313K as of Q1 2017.
  • Aurinia Pharmaceuticals was a new R&F Capital Advisors position in Q1 2017.
  • Aurinia Pharmaceuticals made up 0.08% of R&F Capital Advisors's portfolio in Q1 2017, its #390 holding.
  • 71 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2017.

Based on R&F Capital Advisors's 13F filing for Q1 2017, filed 15 May 2017.